+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pertuzumab"

Metastatic Breast Cancer Treatment Market Report 2025 - Product Thumbnail Image

Metastatic Breast Cancer Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
HER2 Positive Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

HER2 Positive Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • August 2024
  • 180 Pages
  • Global
From
Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Breast Cancer Pipeline Analysis Report - Product Thumbnail Image

Breast Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Breast Cancer Therapeutics - A Global Market Overview - Product Thumbnail Image

Breast Cancer Therapeutics - A Global Market Overview

  • Report
  • November 2024
  • 257 Pages
  • Global
From
From
UAE Breast Cancer Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F - Product Thumbnail Image

UAE Breast Cancer Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • January 2025
  • 82 Pages
  • United Arab Emirates United Arab Emirates
From
From
Breast Cancer Treatment Market Report and Forecast 2023-2031 - Product Thumbnail Image

Breast Cancer Treatment Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
From
From
  • 15 Results (Page 1 of 1)
Loading Indicator

Pertuzumab is a monoclonal antibody used in the treatment of breast cancer. It is used in combination with other drugs, such as trastuzumab and chemotherapy, to treat HER2-positive breast cancer. Pertuzumab works by blocking the HER2 receptor, which is found on the surface of some cancer cells. This prevents the cancer cells from receiving signals that promote their growth and survival. Pertuzumab is approved for use in combination with trastuzumab and chemotherapy for the treatment of HER2-positive metastatic breast cancer. It is also approved for use in combination with trastuzumab and docetaxel for the treatment of HER2-positive early-stage breast cancer. Companies in the Pertuzumab market include Roche, Merck, Pfizer, and AstraZeneca. Show Less Read more